Astria Therapeutics Inc., a biopharmaceutical company focused on therapies for allergic and immunologic diseases, will present at the Eastern Allergy Conference in Palm Beach, Florida, on May 30, 2025. Dr. Raffi Tachdjian from UCLA will present data on the reduction of attack severity in patients with Hereditary Angioedema from the ALPHA-STAR Phase 1b/2 trial of navenibart.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astria Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250522021546) on May 22, 2025, and is solely responsible for the information contained therein.